Brokerage firm Nomura has increased its price target for Zydus Lifesciences to Rs 1,450, reflecting optimism around the company's expansion into biosimilars and specialized medical areas. While the firm notes a robust core business, investors should monitor how aggressive research and development spending, which has nearly doubled, affects future margins. The outlook considers the company's pipeline for niche products in the US market.
Nomura has updated its view on Zydus Lifesciences, setting a new price target of Rs 1,450 per share. The brokerage firm continues to maintain a positive rating on the stock, citing the company's active transition toward high-value pharmaceutical segments as a primary driver for its long-term potential.
The company is currently directing significant capital toward new growth areas, including biologics, medical technology, and contract development and manufacturing. This represents a distinct shift from traditional generic drug manufacturing. Between the 2024 and 2026 financial years, Zydus deployed Rs 136 billion for capacity expansion and acquisitions, representing a 4.5-fold increase compared to the previous three-year block.
Managing Investment Costs and Margins
The primary concern for investors with such rapid expansion is the potential impact on profitability. Research and development expenses have nearly doubled over the past three years, creating pressure on the balance sheet. Despite these rising costs, the company has provided guidance for an EBITDA margin of 24% for the 2027 fiscal year. Nomura expects these margins to remain stable through 2029, even as the company absorbs the costs associated with entering difficult therapeutic areas like rare diseases.
Pipeline Potential and Sector Risks
The long-term strategy relies heavily on the US market, particularly with niche filings such as biosimilars of high-profile drugs like Keytruda and advancements in cell and gene therapy. However, the pharmaceutical sector remains highly competitive. Indian pharmaceutical companies frequently face challenges related to US FDA inspections, which can lead to manufacturing delays, import alerts, or increased compliance costs. Furthermore, the path toward specialized drug development involves high execution risk; heavy R&D spending does not guarantee successful clinical trial results or rapid regulatory approval.
Investors should track how effectively the company balances these capital-intensive investments with its operational requirements. The ability to successfully execute complex filings, maintain stable margins despite high spending, and navigate regulatory scrutiny will be the primary factors determining the success of this strategy in the coming years.